Wegovy weight loss pills for women: what the tablet actually does

Does the pill work the same way as the Wegovy injection?

Yes, the active ingredient is identical: semaglutide. Both the tablet and the injection act on GLP-1 receptors, which play a role in appetite signalling, gastric emptying, and how satisfied you feel after eating. The difference is the delivery system. The tablet uses an absorption enhancer called SNAC so that semaglutide can survive the stomach environment and cross into the bloodstream from the gut lining.

Because absorption through the gut wall is less predictable than a direct subcutaneous injection, the tablet's maintenance dose is 25 mg (far higher by weight than the 2.4 mg weekly injection dose) yet the clinical effect on appetite and weight is broadly comparable. If you want to understand how the tablet formulation compares with other formats, the page covering semaglutide pills for weight loss explains the differences in detail. The semaglutide tablet is not a watered-down alternative; it is a different formulation engineered to reach the same receptor.

One practical point is worth flagging. The tablet must be taken first thing in the morning on an empty stomach, with no more than a small sip of plain water (roughly 120 ml) and you then need to wait at least 30 minutes before eating, drinking anything else (that includes coffee), or taking other oral medicines. That 30-minute window matters for absorption. A quick way to build the habit: take the tablet before you even fill the kettle, then use the wait for your usual morning routine before breakfast.

What did the trial evidence find, and does it apply to women specifically?

The OASIS 4 trial was a phase 3 study involving 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants took the oral tablet alongside lifestyle guidance. The MHRA's approval was underpinned by this evidence. Average weight loss was around 13.6% compared with about 2.4% on placebo. Among participants who stayed fully adherent to the tablet schedule, the average reached approximately 17%, that figure applies specifically to the adherent subgroup and should not be used as a general promise.

The trial did not publish a women-only subgroup as its headline result, so there is no separate figure to quote honestly. What the broader semaglutide programme shows is consistent: the mechanism does not differ by sex, though individual response always varies. Factors like starting weight, metabolic health, and how consistently the tablet is taken tend to have more influence on outcomes than sex alone. If you are curious how this compares with the injection, the Wegovy weight loss pills overview sets out both options side by side.

The most common side effects reported in OASIS 4 were gastrointestinal: nausea, loose stools, vomiting, and indigestion. Around 74% of tablet users experienced at least one GI side effect compared with 42% on placebo, most were mild to moderate and settled over time, particularly after each dose step stabilised. Starting at 1.5 mg and moving up gradually is specifically designed to reduce this burden.

Are there any considerations particular to women taking this medicine?

A few are worth knowing before you speak to a prescriber. If you take an oral contraceptive pill, tirzepatide (Mounjaro) has a documented interaction, but current NHS guidance notes there is no equivalent evidence of the pill's absorption being affected by semaglutide. That said, any question about contraception and a new medicine is worth raising with your prescriber at the outset.

Wegovy tablets are not recommended during pregnancy, while breastfeeding, or for anyone who is actively trying to conceive. The MHRA advises using effective contraception during treatment and for a wash-out period before attempting pregnancy. Under-18s are not a licensed population for this medicine. If any of these situations apply to you, be clear about them during your consultation, a prescriber's job is to make the assessment in full, not to tick a box. The NHS semaglutide medicines page has a clear summary of who should not take it.

HRT is a common question too, especially for women in perimenopause or menopause. Unlike the situation with tirzepatide, there is no specific NHS guidance recommending a switch to transdermal HRT for oral semaglutide users, but any changes to hormone therapy should be discussed with whoever manages that prescription. The oral Wegovy overview covers the storage and administration points in more detail.

What does eligibility look like, and how does the prescription process work?

The licensed criteria for the Wegovy tablet are a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone is not sufficient, the prescriber assesses the broader clinical picture, including your medical history, current medicines, and any contraindications.

The oral tablet is not yet available on the NHS; a NICE appraisal would need to take place first. For now, it is prescribed privately. At nume, a consultation with our clinical team is reviewed the same day by a GPhC-registered Independent Prescriber, a named clinician reads your answers, not software. If the tablet is clinically suitable, the prescription is issued and treatment dispatched the same working day for free next-working-day delivery. There are no subscriptions and no auto-renewals; each repeat order goes through the same clinical check.

For context on what private treatment costs, the Wegovy pill cost page covers how pricing works and what a legitimate price includes. The short version: a genuine private prescription covers the clinical assessment, the prescription itself, and the medicine, any headline figure that skips those elements is not a fair comparison. If you want to explore weight loss treatment options more broadly before deciding, that is a sensible place to start.